Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Biohaven Ltd. (BHVN – Research Report), Zoetis (ZTS – Research Report) and Ginkgo Bioworks Holdings (DNA – Research Report).
Biohaven Ltd. (BHVN)
BTIG analyst Thomas Shrader maintained a Buy rating on Biohaven Ltd. yesterday and set a price target of $59.00. The company’s shares closed last Friday at $53.08.
According to TipRanks.com, Shrader is a 4-star analyst with an average return of
Currently, the analyst consensus on Biohaven Ltd. is a Strong Buy with an average price target of $59.50, which is an 11.2% upside from current levels. In a report issued on April 9, RBC Capital also maintained a Buy rating on the stock with a $61.00 price target.
See the top stocks recommended by analysts >>
Zoetis (ZTS)
In a report released yesterday, Balaji Prasad from Barclays maintained a Buy rating on Zoetis, with a price target of $260.00. The company’s shares closed last Friday at $149.98, close to its 52-week low of $148.48.
According to TipRanks.com, Prasad is a 3-star analyst with an average return of
Zoetis has an analyst consensus of Strong Buy, with a price target consensus of $219.00, representing a 40.5% upside. In a report issued on April 2, Stifel Nicolaus also maintained a Buy rating on the stock with a $195.00 price target.
Ginkgo Bioworks Holdings (DNA)
BTIG analyst Mark Massaro reiterated a Hold rating on Ginkgo Bioworks Holdings on April 12. The company’s shares closed last Friday at $1.01, close to its 52-week low of $0.99.
According to TipRanks.com, Massaro has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on Ginkgo Bioworks Holdings is a Hold with an average price target of $2.03.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BHVN:
